Differential immune responses mediated by adenovirus-and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model

Gene Therapy

Volumn 18, Issue 10, 2011, Pages 986-995

  Felizardo, T C ^a   Wang, J C M ^b   McGray, R A J ^c   Evelegh, C ^c   Spaner, D E ^b,d   Fowler, D H ^e   Bramson, J L ^c   Medin, J A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

adenovirus; dendritic cells vaccine; HER 2 neu; lentivirus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON;

ADENOVIRUS INFECTION; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELLULAR IMMUNITY; DENDRITIC CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; LENTIVIRUS INFECTION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR XENOGRAFT;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENES, ERBB-2; GENETIC VECTORS; IMMUNOTHERAPY; INTERFERON-GAMMA; LENTIVIRUS; MICE; NEOPLASMS; RATS;

ADENOVIRIDAE; LENTIVIRUS; MUS; RATTUS;

EID: 80054088221     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.53     Document Type: Article

References (36)

1. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000; 62: 245-252.
2. Fendly BM, Kotts C, Vetterlein D, Lewis GD, Winget M, Carver ME et al. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 1990; 9: 449-455. (Pubitemid 20366157)
3. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-1857. (Pubitemid 34048651)
4. Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 2006; 5: 717-732. (Pubitemid 46021052)
5. Loisel-Meyer S, Foley R, Medin JA. Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 2008; 13: 3202-3214. (Pubitemid 351594679)
6. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267. (Pubitemid 26119138)
7. Ailles LE, Naldini L. HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 31-52. (Pubitemid 34259336)
8. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377. (Pubitemid 44788976)
9. Loisel-Meyer S, Felizardo T, Mariotti J, Mossoba ME, Foley JE, Kammerer R et al. Potent induction of B-and T-cell immunity against human carcinoembryonic antigenexpressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther 2009; 8: 692-702.
10. Chapatte L, Colombetti S, Cerottini JC, Levy F. Efficient induction of tumor antigenspecific CD8+ memory T cells by recombinant lentivectors. Cancer Res 2006; 66: 1155-1160. (Pubitemid 43165985)
11. Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M et al. Induction of ErbB-2/neuspecific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Therapy 2001; 8: 316-323. (Pubitemid 32237065)
12. Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R et al. Enhanced HER-2/neuspecific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther 2002; 9: 778-786. (Pubitemid 34971309)
13. Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 2008; 16: 607-617. (Pubitemid 351315002)
14. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005; 113: 67-77. (Pubitemid 39507312)
15. Hirschowitz EA, Weaver JD, Hidalgo GE, Doherty DE. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Therapy 2000; 7: 1112-1120. (Pubitemid 30458802)
16. Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res 2002; 62: 5260-5266. (Pubitemid 35024600)
17. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM, Takayama T et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaBdependent pathway. J Virol 2000; 74: 9617-9628.
18. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999; 162: 6378-6383. (Pubitemid 29309357)
19. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29: 964-972. (Pubitemid 29119077)
20. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8: 1355-1363. (Pubitemid 27445416)
21. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002; 100: 1734-1741. (Pubitemid 34925152)
22. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174: 4228-4236. (Pubitemid 40396003)
23. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-5354. (Pubitemid 46890556)
24. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-650.
25. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999; 96: 1036-1041.
26. Cerutti A, Qiao X, He B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol 2005; 83: 554-562. (Pubitemid 41805759)
27. Tang F, Du Q, Liu YJ. Plasmacytoid dendritic cells in antiviral immunity and autoimmunity. Sci China Life Sci 2010; 53: 172-182.
28. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118: 1165-1175. (Pubitemid 351364623)
29. Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007; 121: 149-157. (Pubitemid 46663098)
30. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007; 178: 1534-1541. (Pubitemid 46154624)
31. Dai B, Yang L, Yang H, Hu B, Baltimore D, Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009; 106: 20382-20387.
32. Roth MD, Cheng Q, Harui A, Basak SK, Mitani K, Low TA et al. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol 2002; 169: 4651-4656. (Pubitemid 35178246)
33. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116. (Pubitemid 41724633)
34. Yang TC, Millar J, Groves T, Grinshtein N, Parsons R, Takenaka S et al. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006; 176: 200-210. (Pubitemid 43023264)
35. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
36. Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 2004; 101: 16909-16914. (Pubitemid 39601337)